Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis (Protocol)

Kanie, T., Mizuno, A., Yoneoka, D., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O. and Kwong, J. S. (2020) Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis (Protocol). Cochrane Database of Systematic Reviews, 2020(6), CD013650. (doi: 10.1002/14651858.cd013650) (PMCID:PMC7387055)

[img] Text
219620.pdf - Published Version

238kB

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To systematically review the available evidence on the effects (benefits and harms) of DPP‐4 inhibitors, GLP‐1 receptor agonists, and SGLT‐2 inhibitors in people with established CVD, using network meta‐analysis.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Wu, Professor Olivia
Authors: Kanie, T., Mizuno, A., Yoneoka, D., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O., and Kwong, J. S.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Cochrane Database of Systematic Reviews
Publisher:Wiley
ISSN:1469-493X
Published Online:24 June 2020
Copyright Holders:Copyright © 2020 The Cochrane Collaboration
First Published:First published in Cochrane Database of Systematic Reviews 2020(6): CD013650
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record